Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Kovacs, R. Maier, E. Aberer, M. Brodmann, W. Graninger, X. Kqiku, S. Scheidl, N. Troester, C. Hesse, L. Rubin, H. Olschewski (Austria; San Diego, United States Of America). The progression towards pulmonary arterial hypertension is attenuated by bosentan in scleroderma patients. Eur Respir J 2010; 36: Suppl. 54, 205

Member's Comments

No comment yet.

Related content which might interest you: Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment Source: Eur Respir J 2014; 43: 1516-1519 Year: 2014 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Differential response to the addition of sildenafil to bosentan monotherapy between idiopathic and scleroderma-associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Pulmonary hypertension and arterial stiffness in patients with systemic scleroderma Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Longer-term survival in paediatric patients with idiopathic or familial pulmonary arterial hypertension treated with bosentan Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 405-413 Year: 2015 Macitentan reduces progression of TGF-ß1-induced pulmonary fibrosis and pulmonary hypertension Source: Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017 Year: 2018 Changing serum cytokines levels in patients with idiopathic pulmonary arterial hypertension treated with bosentan Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Comparing cardiopulmonary responses to incremental exercise in patients with chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension Source: Annual Congress 2011 - Altered mechanisms during exercise in disease Year: 2011 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Plasma big-endothelin and hemodynamics in patients with pulmonary arterial hypertension compared to patients with chronic left heart failure with and without pulmonary venous hypertension Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Bosentan influence on catecholamines levels in patients with idiopathic arterial pulmonary hypertenson Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012